Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Andriole, Chief Executive Officer, will participate in a Targeted Oncology Panel at the TD Cowen 44th Annual Health Care Conference on Tuesday, March 5, 2024 at 12:50 p.m. ET.

An audio webcast of the panel discussion will be available on the Investor Relations section of Chimerix's website at ir.chimerix.com, where it will be archived for approximately 90 days.

About Chimerix

Chimerix is a biopharmaceutical company with a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The Company’s most advanced clinical-stage development program, ONC201, is in development for H3 K27M-mutant glioma.

CONTACT:        Will O’ConnorStern Investor Relations212-362-1200will@sternir.com

Grafico Azioni Chimerix (NASDAQ:CMRX)
Storico
Da Dic 2024 a Gen 2025 Clicca qui per i Grafici di Chimerix
Grafico Azioni Chimerix (NASDAQ:CMRX)
Storico
Da Gen 2024 a Gen 2025 Clicca qui per i Grafici di Chimerix